Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

NCT01430754 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-24-Hour Sleep-Wake Disorder

Interventions

DRUG: tasimelteon
DRUG: Placebo

Sponsor

Vanda Pharmaceuticals